In Section C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Members will get treatment until finally condition progression or even the individuals are not able to tolerate the study drugs. - Participant eaten grapefruit or grapefruit products within 3 days ahead https://lorenzoesfpc.smblogsites.com/31953287/abbv-744-cancer-treatment-clinical-trials-an-overview